183 related articles for article (PubMed ID: 12932009)
1. Synthesis and biological evaluation of cytostatin analogues.
Bialy L; Waldmann H
Chem Commun (Camb); 2003 Aug; (15):1872-3. PubMed ID: 12932009
[TBL] [Abstract][Full Text] [Related]
2. Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.
Bialy L; Waldmann H
Chemistry; 2004 Jun; 10(11):2759-80. PubMed ID: 15195307
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of the stereostructure of (+)-cytostatin by fluorous mixture synthesis of four candidate stereoisomers.
Jung WH; Guyenne S; Riesco-Fagundo C; Mancuso J; Nakamura S; Curran DP
Angew Chem Int Ed Engl; 2008; 47(6):1130-3. PubMed ID: 18175302
[No Abstract] [Full Text] [Related]
4. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
Lawhorn BG; Boga SB; Wolkenberg SE; Colby DA; Gauss CM; Swingle MR; Amable L; Honkanen RE; Boger DL
J Am Chem Soc; 2006 Dec; 128(51):16720-32. PubMed ID: 17177422
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of three novel scyphostatin analogues as neutral sphingomyelinase inhibitors.
Pitsinos EN; Wascholowski V; Karaliota S; Rigou C; Couladouros EA; Giannis A
Chembiochem; 2003 Nov; 4(11):1223-5. PubMed ID: 14613115
[No Abstract] [Full Text] [Related]
7. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Shan HB; Cai YC; Liu Y; Zeng WN; Chen HX; Fan BT; Liu XH; Xu ZL; Wang B; Xian LJ
Anticancer Drugs; 2006 Sep; 17(8):905-11. PubMed ID: 16940800
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
[TBL] [Abstract][Full Text] [Related]
9. Total synthesis of alpha-pyrone meroterpenoids, novel bioactive microbial metabolites.
Sunazuka T; Omura S
Chem Rev; 2005 Dec; 105(12):4559-80. PubMed ID: 16351054
[No Abstract] [Full Text] [Related]
10. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A.
Kawada M; Amemiya M; Ishizuka M; Takeuchi T
Biochim Biophys Acta; 1999 Nov; 1452(2):209-17. PubMed ID: 10559474
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
12. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.
Selness SR; Devraj RV; Devadas B; Walker JK; Boehm TL; Durley RC; Shieh H; Xing L; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Messing D; Yang J; Mao MK; Yalamanchili G; Vonder Embse R; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4066-71. PubMed ID: 21641211
[TBL] [Abstract][Full Text] [Related]
13. Cell permeation of a Trypanosoma brucei aldolase inhibitor: evaluation of different enzyme-labile phosphate protecting groups.
Azéma L; Lherbet C; Baudoin C; Blonski C
Bioorg Med Chem Lett; 2006 Jul; 16(13):3440-3. PubMed ID: 16632348
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of the protein phosphatase 2A inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin.
Bialy L; Waldmann H
Angew Chem Int Ed Engl; 2002 May; 41(10):1748-51. PubMed ID: 19750704
[No Abstract] [Full Text] [Related]
15. Kojic acid-tripeptide amide as a new tyrosinase inhibitor.
Noh JM; Kwak SY; Kim DH; Lee YS
Biopolymers; 2007; 88(2):300-7. PubMed ID: 17211869
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors.
Dallavalle S; Gattinoni S; Mazzini S; Scaglioni L; Merlini L; Tinelli S; Beretta GL; Zunino F
Bioorg Med Chem Lett; 2008 Feb; 18(4):1484-9. PubMed ID: 18248813
[TBL] [Abstract][Full Text] [Related]
17. Spirastrellolide A: revised structure, progress toward the relative configuration, and inhibition of protein phosphatase 2A.
Williams DE; Lapawa M; Feng X; Tarling T; Roberge M; Andersen RJ
Org Lett; 2004 Jul; 6(15):2607-10. PubMed ID: 15255702
[TBL] [Abstract][Full Text] [Related]
18. Structure-based drug design of new leads for phosphatase research.
Combs AP
IDrugs; 2007 Feb; 10(2):112-5. PubMed ID: 17285463
[TBL] [Abstract][Full Text] [Related]
19. A new series of 3-alkyl phosphate derivatives of 4,5,6,7-tetrahydro-1-D-ribityl-1H-pyrazolo[3,4-d]pyrimidinedione as inhibitors of lumazine synthase: design, synthesis, and evaluation.
Zhang Y; Jin G; Illarionov B; Bacher A; Fischer M; Cushman M
J Org Chem; 2007 Sep; 72(19):7176-84. PubMed ID: 17705537
[TBL] [Abstract][Full Text] [Related]
20. The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity.
Aggen JB; Humphrey JM; Gauss CM; Huang HB; Nairn AC; Chamberlin AR
Bioorg Med Chem; 1999 Mar; 7(3):543-64. PubMed ID: 10220039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
